The product, a targeted therapy for HER2-positive breast cancer, has been introduced through a semi-exclusive collaboration with Enzene Biosciences Ltd.
For the next three years nutritional kits would be supplied to the patients at their doorsteps every month. A budget of Rs 1.5 crore has been allotted for the purpose, said Dr. B Partha Saradhi Reddy
Hyderabad: Hyderabad-headquartered pharma company Hetero said it acquired a manufacturing plant at Penjerla village of Kothur mandal in Mahbubnagar. The company committed an investment of about Rs.600 crore to upgrade and enhance the existing facilities at the site. This will add about 2,000 jobs in biochemistry, pharmaceutical sciences, molecular biosciences, engineering, and ancillary services. The […]
Hyderabad: Pharma player Hetero announced that its biologics arm ‘Hetero Biopharma’ has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture Sputnik Light. Hetero is the first biopharmaceutical company in India to receive manufacturing and marketing (M&M) approval for the product manufactured locally for the prevention of COVID-19 in adults aged over […]
Visakhapatnam: The Communist Party of India (Marxist) has demanded a thorough investigation into the accident at Hetero drugs unit in the district and compensation of Rs. One crore to Allada Sairam, 23, who died in the accident on Wednesday. In a letter addressed to the District Collector here on Thursday, CPI(M) district secretary K. Lokanadham […]
Hyderabad: Hyderabad-based Hetero unveiled results of phase III trials of Movfor (Molnupiravir), an investigational oral antiviral Covid-19 drug. The company demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. The results were presented as an oral abstract at the Conference on […]
Hyderabad: Hyderabad-based Hetero, a vertically integrated pharmaceutical organisation, has received Drug Controller General of India (DCGI) nod for manufacture and marketing of molnupiravir capsules 200 mg (Movfor). Molnupiravir is an oral antiviral indicated for restricted emergency use in India to treat adult patients with Covid-19. Hetero’s Movfor will be made available in a 40 capsule […]
Hyderabad: Hyderabad-based Hetero Group said that the Drug Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India for the treatment of Covid-19 in hospitalised adults. It is aimed to treat individuals who are receiving systemic corticosteroids and require supplemental oxygen, non- invasive or invasive mechanical […]
Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India
Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation.
The Gamaleya Center and RDIF announced on November 24 positive results obtained during the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers.
According to the RDIF -- Russia's sovereign wealth fund, the vaccine's interim clinical trial results show 95 per cent efficacy on the 42nd day after the first dose.
